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Abstract
Background:The biodegradable polymer drug-eluting stents (DES) were developed to improve vascular healing. However, further
data and longer-term follow-up are needed to confirm safety and efficacy of these stents. This randomized clinical trial aimed to
compare safety and efficacy of 2 sirolimus-eluting stents (SES): Cordimax—a novel abluminal biodegradable polymer SES and
Cypher Select—a durable polymer SES, at 9 months angiographic and 5-year clinical follow-up.
Methods:We randomized 402 patients with coronary artery disease to percutaneous coronary intervention with Cordimax (n=
202) or Cypher select (n=200). Angiographic follow-up was performed at 9 months after the index procedure and clinical follow-up
annually up to 5 years. The primary endpoint was angiographic in-stent late luminal loss (LLL). Secondary endpoints included
angiographic restenosis rate, target vessel revascularization (TVR), and major adverse cardiac events (MACEs; defined as cardiac
death, myocardial infarction, or TVR) at 5-year follow-up.
Results:Cordimax was noninferior to Cypher select for in-stent LLL (0.25±0.47 vs 0.18±0.49mm; P=0.587) and in-stent mean
diameter stenosis (22.19±12.21% vs 19.89±10.79%; P=0.064) at 9 months angiographic follow-up. The MACE rates were not
different at 1 year (5.9% vs 4.0%, P=0.376); however, MACE rates from 2 to 5 years were lower in the Cordimax group (6.8% vs
13.1%; P=0.039).
Conclusion: Abluminal biodegradable polymer SES is noninferior to durable polymer SES at 9-month angiographic and 1-year
clinical follow-up. However, MACE rates from 2 to 5 years were less in the abluminal biodegradable polymer group.
Abbreviations: ARC = Academic Research Consortium, CABG = coronary artery bypass grafting, DES = drug-eluting stents,
LLL= late lumen loss, MACE=major adverse cardiovascular events, MI=myocardial infarction, MLD=minimal lumen diameter, PCI
= percutaneous coronary intervention, QCA = Quantitative coronary angiography, SES = sirolimus-eluting stent, ST = stent
thrombosis, TIMI = thrombolysis in myocardial infarction, TVR = target vessel revascularization.
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11. Introduction
Drug-eluting stents (DES) delivering anti-proliferative drugs from
a durable polymer have significantly reduced angiographic and
clinical measures of restenosis compared with bare metal stents,
with the low risk of adverse events including myocardial
infarction (MI) and death.[1–5] However, durable polymers of
the first-generation DES have been linked with persistent
inflammation, and delayed endothelial healing, which may result
in an increased risk of late and very late stent thrombosis (ST).[6]
Recent advances in stent technology, including thinner struts and
the introduction of biocompatible or biodegradable polymers,
haveminimized the risk of complications compared with the first-
generation DES.[7–12] Several studies have been conducted to test
clinical performance of devices with different biodegradable
polymers, anti-proliferative drugs, and follow-up duration.[13–16]
However, more long-term clinic data are needed to compare
biodegradable polymer versus durable polymer sirolimus-eluting
stents (SES).
Cordimax stents (Rientech Medical, Shandong, China), which
elute sirolimus from abluminal biodegradable polymer, have been
shown to have optimized in vitro drug release kinetics and in vivo
pharmacokinetics. Animal studies have also shown enhanced
endothelialization and vascular healing after stent implantation.[17]
Zhang et al. Medicine (2016) 95:38 MedicineThe aim of this clinical trial was to evaluate the safety and
efficacy of Cordimax abluminal biodegradable SES against
Cypher Select durable polymer SES (Cordis Corporation, New
Jersey), for 9-month angiographic and 5-year clinical follow-up.Figure 1. Structure and polymer material of the stent platforms. Top half of the
figure depicts abluminal coated stent, whereas the bottom panel shows
uniform coating on both luminal and abluminal surfaces.2. Methods
2.1. Study design and participants
This study is a prospective randomized controlled trial compar-
ing Cordimax and Cypher select stents. Trial enrolled 402
patients with a 1:1 ratio to the 2 study arms. Patients were eligible
for enrolment if they were between 18 and 80 years old and
intended to undergo percutaneous coronary intervention (PCI)
treatment of de novo native coronary artery lesions with a
diameter stenosis ≥50% and a reference vessel diameter between
2.5 and 4.0mm by visual estimation. Themajor exclusion criteria
included acute MI within 1 week, chronic total occlusion, left
main coronary artery lesions, bifurcation lesions, and in-stent
restenosis. Angiographic follow-up was conducted at 9 months
after PCI. Clinical follow-up was performed annually up to 5
years. The trial was approved by the institutional ethics
committee. All eligible patients signed written informed consent
for participation in the trial.2.2. Study procedure
Patients were treated with standard interventional techniques.
Pre-dilation and post-dilation were at the discretion of the
treating interventionist. In the event of a bail-out procedure and
additional stent requirement, the stent had to be one from the
same group as the first implanted stent. All patients received
treatment with aspirin (300mg, at least 24hours before the
intervention) and clopidogrel [loading dose: 300mg, at least 6
hours before the intervention; for those having taken clopidogrel
(75mg/day) for more than 72hours, no loading dose was
needed]. Anticoagulation with heparin during the procedure was
administered according to the protocol recommendations. Dual
antiplatelet therapy with aspirin (100mg/day) and clopidogrel
(75mg/day) was continued for at least 12 months.
2.3. Stents
Cordimax stent has 316L stainless steel platform coated on
abluminal surface with a biodegradable polymer polylactide-co-
polyglycolide copolymer (75:25 ratio) mixed with anti-prolifer-
ative drug sirolimus (Fig. 1). Cypher select is also a 316L stainless
steel stent but coated with a durable polymer (Polyethylene-co-
vinyl acetate and Poly n-butyl methacrylate). Both stents have
similar drug dose (sirolimus 1.4mg/mm2).[17] The Cordimax stent
was available in diameters of 2.25, 2.5, 2.75, 3.0, 3.5, and 4.0
mm and in lengths of 9, 12, 14, 16,18, 20, 23, 25, 28, and 33mm.
The Cypher select stents were available in diameters of 2.25, 2.5,
2.75, 3.0, 3.5, and 4.0mm and in lengths of 12, 15, 18, 23, 28,
and 33mm.
2.4. The study endpoints and follow-up
The primary endpoint of the study was in-stent late lumen loss
(LLL) at 9 months. Secondary endpoints included device, lesion,
and clinical success rates (device success was defined as
the attainment of <50% residual stenosis of the target lesion
using only the assigned device; lesion success was defined as
the attainment of <50% residual stenosis, thrombolysis in2myocardial infarction (TIMI) 3 flow, no residual dissection, and
thrombosis of the target lesion; clinical success was defined as
attainment of lesion success of the target lesion and no in-hospital
adverse cardiac events; in-stent and in-segment binary restenosis
rates, in-segment LLL, in-stent and in-segment percentage
diameter stenosis; MACE, defined as the composite of cardiac
death, MI, and target vessel revascularization; and ST—definite
and probable ST according to ARC (Academic Research
Consortium) definitions (early, late, and very late). MACE and
ST were clinically followed up at 1 month, 6 months, 12 months,
and annually up to 5 years.[18] Quantitative coronary angiogra-
phy (QCA) analysis was performed at baseline and 9 months
follow-up. All angiograms were evaluated by an independent
specialist in core laboratory (Zhongshan Hospital Fudan
University, Shanghai) using the QAngio XA Version 7.2 Analysis
Software (Medis Medical Imaging System Inc., Leiden, The
Netherlands). Standard QCA methodology was used including
analysis of the stent and the peri-stent segments of 5mm proximal
and distal to the stent edge. Binary restenosis was defined in every
segment (5mm proximal, 5mm distal and in-stent) as a >50%
diameter stenosis at follow-up. LLL was defined as the difference
inminimal lumen diameter (MLD) immediately after stenting and
at 9-month follow-up.[19]
2.5. Statistical analysis
The trial was designed to show noninferiority for in-stent LLL at 9
months. A noninferiority margin was 0.15mm. The published
angiographic results of cypher stent showed an in-stent LLL of
0.15±0.39mmat 9months.Assuming an anticipated in-stent LLL
of theCordimax stent of 0.15mmat 9months and a noninferiority
margin of 0.15mm, a 2-sided alpha of 0.05% and 90% statistical
power would require a minimum number of 288 subjects (144
subjects per group). Assuming a loss to angiographic follow-up
rate of 72%, a total sample size of 400 enrolled patients was
required. Other treatment group comparisons were performed
using the 2-sample t test for continuous variables, Fisher exact
Table 1
Baseline clinical and angiographic characteristics of patients.
Characteristics Cordimax (n=202) Cypher (n=200) P
Clinical
Age 59.8±11.5 60.6±10.7 0.496
Male 71.8% 77.5% 0.188
Smoking history 59.3% 53.1% 0.212
Hypertension 55.5% 64.8% 0.055
Diabetes 18.3% 22.1% 0.344
Previous stroke 2.5% 3.6% 0.511
Previous CABG 0% 0.5% 0.314
Previous MI 19.8% 14.4% 0.121
ECG normal 45.5% 45.6% 0.413
CCS/Braundward
I 37.5% 37.4% 0.761
II 55.5% 57.5% 0.679
III 6.5% 4.6% 0.394
IV 0.5% 0.5% 0.994
NYHA
I 17.4% 17.3% 0.655
II 57.1% 58.6% 0.911
III 20.4% 20.9% 0.960
IV 5.1% 3.1% 0.317
Dual antiplatelet therapy 98.5% 98.5% 0.990
Angiographic
Diameter stenosis 65.94±14.27 67.76±15.66 0.161
Lesion length, mm 41.41±25.25 37.74±21.55 0.335
Stents number/person 1.85±1.04 1.56±0.74 0.013∗
Stents diameter, mm 2.78±0.74 2.90±0.70 0.466
Lesion sites
RCA 53.5% 30% 0.001∗
LCX 32.2% 20.5% 0.008∗
LAD 62.4% 68.5% 0.132
CCS=Canadian Cardiovascular Society, ECG=Electrocardiograph, LAD= left anterior descending
artery, LCX= left circumflex artery, MI=myocardial infarction, NYHA=New York Heart Association,
RCA= right coronary artery.
Table 2
Angiographic outcomes at 9-month follow-up.
Outcomes Cordimax (n=145) Cypher (n=154) P
Diameter restenosis, %
In-stent 22.19±12.21 19.89±10.79 0.064
In-segment 27.72±12.50 27.39±12.43 0.793
Target vessel revascularization 5.9% 3.5% 0.249
Minimum lumen diameter 2.10±0.56 2.14±0.56 0.453
Late lumen loss, mm 0.25±0.47 0.18±0.49 0.587
Zhang et al. Medicine (2016) 95:38 www.md-journal.comtest for dichotomous variables, and Cochran-Mantel-Haenszel
(Modified Ridit scores) for ordinal variables with more than 2
categories.All analyseswereperformedwith the SAS9.13 software
(SAS Institute Inc., Cary, NC).3. Results
3.1. Baseline patient and lesion characteristics
In total, 402 patients were randomly assigned 1:1 to treatment
with Cordimax stents or Cypher Select stents. A total of 202
patients allocated to Cordimax group received 380 stents and
200 patients allocated to Cypher Select group received 360 stents.
All patients were clinically followed up to 5-year follow-up.
Baseline clinical and angiographic characteristics are summa-
rized in Table 1. They were balanced in both groups, including
age, gender, and risk factors, including smoking, hypertension,
diabetes, previous stroke, previous MI (MI), previous coronary
artery bypass grafting (CABG), CCS (Canadian Cardiovascular
Society)/Braundward angina pectoris grading, and NYHA (New
York Heart Association) functional class. The use of dual
antiplatelet therapy was high in both Cordimax and Cypher
select groups. The rates of dual antiplatelet therapy were 98.5%
versus 98.5% (P=0.99) at 12 months. Baseline angiographic
characteristics were also consistent between Cordimax and
Cypher Select groups for lesion length, stents diameter, and
diameter stenosis pre-PCI (Table 1). Patients in the Cordimax
group, compared with Cypher Select group, were more likely to3have lesion in right coronary artery (53.5% vs 30%, P=0.001)
than left circumflex artery (32.2% vs 20.5%, P=0.008) and
received more stents per patient (1.85±1.04 vs 1.56±0.74, P=
0.013).3.2. Angiographic outcomes
Angiographic follow-up at 9 months was completed in 299
(74.4%) patients. A total of 145 patients (71.8%) allocated to
Cordimax group and 154 patients (77.0%) allocated to Cypher
select underwent follow-up angiography. Device success (100%
vs 100%, P=1.0) and lesion success (99.98% vs 98.74%, P=
1.0) was high and no different between the 2 groups. According
to the pre-specified noninferiority margin, Cordimax stents were
noninferior to Cypher Select for the primary angiographic end
point of in-stent LLL at 9 months [0.25±0.47 vs 0.18±0.49mm;
difference=0.07±0.48mm; 95% confidence interval (95% CI)
-0.02 to 0.17]. Other angiographic outcomes including percent
in-stents restenosis, percent segment restenosis, and minimum
lumen diameter of target vessel were also not different between
the 2 groups (Table 2).3.3. Clinical outcomes
There were no deaths in Cordimax group and 1 death in Cypher
select group (noncardiovascular cause) during first year. Clinical
event rates during the 5 years follow-up are summarized in
Table 3. The cumulative rate of MACE, TVR, cardiac death, and
MI were comparable for patients in Cordimax and Cypher Select
groups (Table 3). However, it was found that the 2 groups had
significant difference in the cumulative pursue rate of MACE and
TVR from 2 to 5 years (cumulative pursue rate=annual
cumulative rate -1st year rate) (Table 3 and Fig. 2). The
cumulative pursue rates of MACE and TVR in Cordimax were
lower than those of Cypher Select (Fig. 2). There was no ARC-
defined definite and probable ST in the Cordimax group. One
case was proved to be definite very late ST in Cypher Select group
(Table 3).
4. Discussion
Our study has shown that abluminal biodegradable polymer SES
was noninferior to durable polymer SES for angiographic in-stent
LLL at 9-month and MACE at 1-year follow-up. However, the
events rate in the subsequent years tended to be lower in the
abluminal biodegradable polymer group.
Other studies have also shown noninferiority of biodegradable
polymer based DES for angiographic outcomes at 9 to 12 months
follow-up. Our results corroborate with data from LEAD-
ERS,[7,10] ISAR-TEST,[9] CREATE,[8] EVOLVE,[20] and BIO-
FLOW trials.[21] The results therefore confirm the efficacy
of biodegradable polymer DESs against the first-generation
Figure 2. Kaplan-Meier estimates of primary endpoint until 5-year follow-up. BP=biodegradable polymer, DES=drug-eluting stent, PP=permanent polymer.
Zhang et al. Medicine (2016) 95:38 Medicinepermanent-polymer DES. The abluminal biodegradable polymer
SES as compared with durable polymer SES tended to reduce
annual cumulative rate of MACE, TVR, cardiac death, MI, and
ST than durable polymer SES in 5 years follow-up. However, the
differences were not statistically significant (P>0.05). Neverthe-
less, abluminal biodegradable polymer SES showed superiority in
longer term safety, by reducing cumulative pursue rates of
MACE, TVR, and ST in 5 years. Cordimax stent has polylactide-
co-polyglycolide copolymer (75:25 ratio), which degrades into
carbon dioxide andwater after the drug (sirolimus) is released.[17]
These polymers and their degradation products are more
biocompatible and less prone to hypersensitivity reactions.
Although our study was not powered for clinical outcomes,
our results are consistent with other studies and a meta-analysis
suggesting better long-term outcomes with biodegradable
polymer DES. [6,9,13]
Our study had relatively lower incidence of MACE, TVR, and
ST in both groups. This may partly reflect inclusion of relatively
lower risk patients as the major exclusion criteria included acute
MI within 1 week, chronic total occlusion, left main coronary
artery lesions, bifurcation lesions, and in-stent restenosis, which
is different from some other studies.[7,9,10,13,16,20–23]. Further-
more, adherence to optimal medical therapy, especially DAPT
(which was 98% at 1 year), is higher than other trials.[24]
New generation DES have been developed to improve device
performance and safety, with a specific attention at reducingTable 3
Clinical outcomes up to 5 years follow-up.
Clinical outcomes Cordimax (n=202) Cypher Select (n=200) P
At 1-year follow-up
MACE 5.9% 4.0% 0.376
Cardiac death 0.0% 0.5% 0.315
MI 1.0% 0.5% 0.569
Clinically driven TLR 1.5% 1.0% 0.660
TVR 5.0% 3.0% 0.318
ST (definite/probable) 0.0% 0.0% 1.000
At 5-year follow-up
MACE 12.4% 17.0% 0.203
Cardiac death 1.5% 2.5% 0.462
MI 2.0% 3.0% 0.514
Clinically driven TLR 3.0% 4.0% 0.582
TVR 8.9% 11.5% 0.411
ST (definite/probable) 0.0% 0.5% 0.315
MACE=major adverse cardiac event, MI=myocardial infarction, ST= stent thrombosis, TLR= target
lesion revascularization, TVR= target lesion revascularization.
4delayed re-endothelialization and very late ST. Cordimax stent
employs patented technique of the asymmetric coating, smearing,
and modulating drug release, which would be beneficial for the
vascular endothelium to regenerate.[17] The abluminal polymers
tend to effectively prevent the vascular restenosis and decrease the
incidence of late thrombosis, which contribute to reduction in
longer-term adverse events. Further larger scale trials of this
device, powered for clinical outcomes, are warranted.4.1. Limitations
This study has several limitations. First, the sample size was
calculated to assess a difference in LLL, which is a surrogate
endpoint for clinical restenosis. Second, patients included in the
study were selected strictly by angiographic and clinical
characteristics rather than an all-comers set-up; thus, the results
may not be applicable to all patient groups. Finally, the present
study did not include additional intracoronary imaging
guidance (such as intravascular ultrasound, optical coherence
tomography).5. Conclusion
Compared with durable polymer Cypher Select, abluminal
biodegradable polymer Cordimax stents showed similar efficacy
for the primary end point in stent LLL and potentially better
longer term safety for MACE, TVR, and ST.References
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